Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q1 2026 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Arcutis Biotherapeutics, Inc. First Quarter 2026 Earnings Conference Call.
Arcutis Biotherapeutics Inc. (ARQT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Zevenbergen Capital Investments Nancy Zevenbergen | 357,490 | $8,422,464 | -15% | 0.24% |
| 2. | Navellier & Associates Louis Navellier | 13,753 | $324,021 | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.08 | 2,646 | $34,610.47 | 27,448 | 2025-06-13 | Filing | |
| $13.41 | 378 | $5,069.28 | 24,802 | 2025-06-05 | Filing | |
| $13.32 | 1,890 | $25,177.45 | 24,424 | 2025-06-04 | Filing | |
| $13.65 | 2,520 | $34,398.00 | 22,534 | 2025-05-22 | Filing | |
| $13.66 | 2,520 | $34,423.20 | 20,014 | 2025-05-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $23.61 | 884 | $20,871.77 | 126,689 | 2026-05-04 | Filing | |
| $23.27 | 7,372 | $171,543.49 | 127,573 | 2026-05-04 | Filing | |
| $23.61 | 684 | $16,149.65 | 120,466 | 2026-05-04 | Filing | |
| $23.61 | 1,341 | $31,661.81 | 86,413 | 2026-05-04 | Filing | |
| $23.61 | 3,172 | $74,892.82 | 720,755 | 2026-05-04 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,980,770 | $117,346,943 | 0.08% | |
| 2. | 4,871,536 | $114,773,388 | 0% | |
| 3. | 3,329,224 | $78,436,518 | 0.01% | |
| 4. | 1,954,685 | $46,052,379 | 0% | |
| 5. | 1,086,651 | $25,601,498 | 0.13% |
News See All
10 Overlooked Growth Stocks to Buy Now
On April 14, Tom Lee, Fundstrat's Head of Research, joined CNBC's 'Power Lunch' to discuss his outlook on equities.
13 Best Growth Stocks to Buy Right Now
On March 16, Chief Investment Strategist at Hightower Stephanie Link and Chief Investment Officer at NFJ Investment Group John Mowrey joined CNBC to discuss oil shocks and market opportunities.
Guggenheim Raises Its Price Target on Arcutis Biotherapeutics, Inc. (ARQT) to $35 and Maintains a Buy Rating
On February 27, 2026, Guggenheim raised its price target on Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) to $35 from $34 and maintained a Buy rating.
10 Fastest Growing NASDAQ Stocks to Buy
High growth stocks have once again taken center stage, and major asset managers argue that earnings momentum remains the decisive factor. In its 2026 Year-Ahead Investment Outlook, J.P.
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by. Welcome to the Arcutis Biotherapeutics, Inc. Fourth Quarter Fiscal Year 2025 Earnings Conference Call.
Baron Health Care Fund is Expecting High Operating Margins for Arcutis Biotherapeutics (ARQT)
Baron Funds, an investment management company, released its fourth-quarter investor letter for the “Baron Health Care Fund”. A copy of the letter can be downloaded here.
Arcutis (ARQT) Soars to Record High on Swing to Profitability, 'More-Than-Double' Revenues
Arcutis jumped to a fresh record high on Tuesday, as investors cheered a stellar earnings performance in the third quarter of the year, having more than doubled its revenues to reach profitability during...
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2025 Earnings Call Transcript
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2025 Earnings Call Transcript October 28, 2025Arcutis Biotherapeutics, Inc. beats earnings expectations.
Arcutis Biotherapeutics, Inc. (ARQT) Eyes Pediatric Expansion for ZORYVE Cream
Arcutis Biotherapeutics, Inc.
Hedge Fund Resource Center